Re: Deng and Heybati.

This document is a response to comments made by Deng and Heybati regarding a review on the potential role of artificial intelligence (AI) in clinical trial enrollment. The authors acknowledge the limitations of their review, including the heterogeneity of AI workflows and funding sources across published studies. They agree that further investigations are needed to better understand the implications of AI in different steps of the enrollment process and to explore the parameters of AI algorithms. The authors also caution against dismissing industry-supported studies and emphasize the importance of transparency and validation in future investigations. They acknowledge the presence of biases in review articles and encourage critical thinking and dialogue. The document concludes by thanking Deng and Heybati for their comments and interest in the article. [Extracted from the article]